Although BRCA1/2 mutations are not characteristic of AML, several pre-clinical studies have demonstrated genomic mutations which provide a rationale for PARPi use in AML therapy (reviewed in Faraoni et al., 2019). Here, BRCA1 is linked to acute myeloid leukemia.